Amylyx believes it has found a disease-modifying therapy in AMX0035, as other key readouts approach.
Other groups with large disconnects between sellside and investor expectations include Beigene, Alnylam and Acceleron.
A global pandemic has done nothing to crimp M&A premiums, with acquirers forced to swallow ever higher price tags.
The $6.5bn price – biopharma’s biggest buyout of the year so far – shows how competitive the anti-FcRn space has become.
This week another takeover included a CVR element, confirming a trend that has been gaining traction over the past year.
Second-quarter deal values plummeted as Covid-19 spread and the prices of target companies spiralled.